CBMのチャート
CBMの企業情報
| symbol | CBM |
|---|---|
| 会社名 | Cambrex Corp （CAMBREX CORP） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | ケンブレックス(Cambrex Corporation)は、ライフサイエンス企業であり、製品並びにジェネリック医薬品の開発及び商品化サービスを提供する。同社は、単一セグメントとして集約される製造施設である4つの事業セグメントを通じて事業を行う。同社の製造設備は、Cambrex Charles City Inc.、Cambrex Karlskoga AB及びCambrex Profarmaco Milano S.r.lを含む子会社によって所有される。 同社の製品は、活性医薬成分（API）と医薬品中間体で構成される。同社は、カスタム有機合成及びプロセス開発、APIの最新製造技術（cGMP）製造、グラムから数百キログラムまでの中間体、cGMP分析サービス、規制物質研究開発（R＆D）及び製造、スケジュールII- V並びにコントラクト研究を提供する。同社は、米国及び欧州にはAPI R＆D及びcGMP施設があり、90種類以上の汎用APIを提供する。 キャンブレックスは、米国のライフサイエンス企業。有機化学を元に医薬成分を開発・製造する。主に開発者や製薬会社に対し、活性医薬成分や医薬中間体製品や関連サ―ビスを提供。また、R&D施設や製造施設は米国のほかにヨ―ロッパとインドにも展開。本社はニュ―ジャ―ジ―州。 Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ. |
| 本社所在地 | One Meadowlands Plaza East Rutherford NJ 07073 USA |
| 代表者氏名 | Steven Mark Klosk |
| 代表者役職名 | President Chief Executive Officer Director |
| 電話番号 | +1 201-804-3000 |
| 設立年月日 | 29921 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 1732人 |
| url | www.cambrex.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 150.45300 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 1309.17000 |
| 売上高 | （百万ドル） 532.09300 |
| 企業価値(EV) | （百万ドル） 1513.31800 |
| 当期純利益 | （百万ドル） 91.27000 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Cambrex Corporation revenues decreased less than 1% to $532.1M. Net income before extraordinary items decreased 12% to $91.3M. Revenues reflect Finished Dosage Form (FDF) segment increase from $0K to $25.9M North America segment increase of 7% to $183M Other segment increase of 23% to $12.9M also reflect Active Pharmaceutical Ingredients (APIs) segment decrease of 7% to $489.1M. |
CBMのテクニカル分析
CBMのニュース
Permira Funds To Acquire Cambrex In $2.4B Deal 2019/08/07 12:07:50 Benzinga
Cambrex (NYSE: CBM ) shares are trading sharply higher after the company announced it will be acquired by the Permira Funds in a deal valued around $2.4 billion. Cambrex shareholders will receive $60 in cash for each share of Cambrex common stock, which represents a 47.1% premium to the August 6 closing stock price and a 37.3% premium to the 60-day volume … Full story available on Benzinga.com
Cambrex stock rockets after $2.4 billion buyout deal at a 60% premium 2019/08/07 10:46:00 MarketWatch
Shares of Cambrex Corp. rocketed 47% in toward a 10-month high in premarket trading Wednesday, after drug product and analytical services company agreed to…
Cambrex Corporation (CBM) CEO Steven Klosk on Q1 2019 Results - Earnings Call Transcript 2019/05/05 12:01:05 Seeking Alpha
Cambrex's (CBM) CEO Steve Klosk on Q4 2018 Results - Earnings Call Transcript 2019/02/13 17:06:03 Seeking Alpha
Cambrex Corporation (NYSE:CBM) Q4 2018 Earnings Conference Call February 13, 2019, 8:30 am ET Company Participants Greg Sargen - CFO Steve Klosk - President &am
Permira Funds To Acquire Cambrex In $2.4B Deal 2019/08/07 12:07:50 Benzinga
Cambrex (NYSE: CBM ) shares are trading sharply higher after the company announced it will be acquired by the Permira Funds in a deal valued around $2.4 billion. Cambrex shareholders will receive $60 in cash for each share of Cambrex common stock, which represents a 47.1% premium to the August 6 closing stock price and a 37.3% premium to the 60-day volume … Full story available on Benzinga.com
Cambrex stock rockets after $2.4 billion buyout deal at a 60% premium 2019/08/07 10:46:00 MarketWatch
Shares of Cambrex Corp. rocketed 47% in toward a 10-month high in premarket trading Wednesday, after drug product and analytical services company agreed to…
Cambrex Corporation (CBM) CEO Steven Klosk on Q1 2019 Results - Earnings Call Transcript 2019/05/05 12:01:05 Seeking Alpha
Cambrex's (CBM) CEO Steve Klosk on Q4 2018 Results - Earnings Call Transcript 2019/02/13 17:06:03 Seeking Alpha
Cambrex Corporation (NYSE:CBM) Q4 2018 Earnings Conference Call February 13, 2019, 8:30 am ET Company Participants Greg Sargen - CFO Steve Klosk - President &am
Permira Funds To Acquire Cambrex In $2.4B Deal 2019/08/07 12:07:50 Benzinga
Cambrex (NYSE: CBM ) shares are trading sharply higher after the company announced it will be acquired by the Permira Funds in a deal valued around $2.4 billion. Cambrex shareholders will receive $60 in cash for each share of Cambrex common stock, which represents a 47.1% premium to the August 6 closing stock price and a 37.3% premium to the 60-day volume … Full story available on Benzinga.com
Cambrex stock rockets after $2.4 billion buyout deal at a 60% premium 2019/08/07 10:46:00 MarketWatch
Shares of Cambrex Corp. rocketed 47% in toward a 10-month high in premarket trading Wednesday, after drug product and analytical services company agreed to…